Puma Biotechnology PBYI will be releasing its next round of earnings this Thursday, Feb. 28. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement.
Earnings and Revenue
Analysts covering Puma Biotechnology have modeled for quarterly EPS loss of 77 cents on revenue of $53.65 million.
Puma Biotechnology reported a per-share loss of $1.03 when it published results during the same quarter last year. Sales in that period totaled $20.1 million. The Wall Street consensus estimate for earnings would represent a 25.24 percent decrease for the company. Sales would be have grown 166.92 percent from the same quarter last year. Puma Biotechnology's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | -0.97 | -1.26 | -1 | -1.98 |
| EPS Actual | 0.16 | -0.59 | 0.03 | -1.03 |
Stock Performance
Over the last 52-week period, shares of Puma Biotechnology have declined 58.49 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Long-term shareholders are already wary of 12-month losses prior to the announcement.
Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The most common rating by analysts on Puma Biotechnology stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
